Cashu FinanceCashu Finance
  • Terminal
  • Pulse
  • Spotlight
  • News
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Healthcare
  3. OTC
  4. BAYRY

Market Cap: $60.32B

BA

Bayer AG

BAYRY
OTC (Other OTC)USD
Invest in BAYRY
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksScreenersAboutAuthorsAdvertisersBrokersConferencesContact

Legal

Terms of ServicePrivacy PolicyEditorial PolicyCorrections Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

$15.35
-$0.08(-0.52%)
At close: Nov 18, 22:41 EST

More on Bayer AG

  • News & announcements
  • Financials

Bayer AG at a Glance

  • Loss-making over the last 12 months (net margin -3.8%).

Open

$14.88

Prev. Close

$15.43

High

$14.90

Low

$14.52

Key Statistics

52-Week Range92% of range
Low $7.65High $15.98
Market Cap
$60.32B
P/E Ratio
n/m (loss-making)
EPS (TTM)
-$0.44
Revenue (TTM)
$45.88B
Dividend Yield
0.24%
Price / Book
1.53x
Beta
0.83
Avg. Volume
706.41K

Company Profile

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

CEOBill Anderson
SectorHealthcare
IndustryDrug Manufacturers - General
Employees88.1K
IPO DateNov 18, 1996
ExchangeOTC
Exchange NameOther OTC
CurrencyUSD
Headquarters & Contact
AddressKaiser-Wilhelm-Allee 1
City / State / ZIPLeverkusen, NW, 51368
CountryGermany
Phone

BAYRY Stock FAQ

What does Bayer AG do?

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments.

Where is Bayer AG stock listed?

Bayer AG trades on the Other OTC under the ticker BAYRY, priced in USD.

What is Bayer AG's market cap?

Bayer AG has a market capitalisation of $60.32B, based on its latest share price.

What is the P/E ratio of BAYRY?

BAYRY has no meaningful P/E ratio because it reported a loss over the last 12 months.

What is BAYRY's 52-week high and low?

Over the past 52 weeks BAYRY has traded between $7.65 and $15.98.

Does Bayer AG pay a dividend?

Yes. Bayer AG's dividend yields 0.24% at the current share price.

Is Bayer AG profitable?

Loss-making over the last 12 months (net margin -3.8%).

What do analysts think of BAYRY stock?

The analyst consensus rating for BAYRY is Hold.

Who is the CEO of Bayer AG?

Bill Anderson is the CEO of Bayer AG, which is headquartered in Leverkusen.

Shares trade 58% below a discounted cash flow (DCF) estimate of $36.73.
  • Moderate debt: borrowings are 1.30x shareholders' equity.
  • Altman Z-Score of 1.09 is in the distress zone, which signals higher bankruptcy risk.
  • Analyst consensus rating: Hold.
  • Pays a dividend yielding 0.24%.
  • Generated automatically from reported financial data. General information only, not financial advice.

    Fundamentals Scorecard

    Each pillar is scored out of 5 from the latest reported data.

    • Valuation

      Fair · 2.7/5

      Price vs earnings, book value and discounted cash flow.

    • Profitability

      Weak · 1.0/5

      Return on equity and return on assets.

    • Financial Health

      Weak · 1.0/5

      Debt levels and Altman Z-Score bankruptcy risk.

    • Fundamental Trend

      Fair · 2.8/5

      Piotroski F-Score: 9 checks on profit, leverage and efficiency.

    See the full financial breakdown →

    Recently from Cashu

    Bayer AG's Growth Potential from U.S. Defense Production Act Focusing on Herbicide Supply

    Bayer AG Poised to Benefit from U.S. Defense Production Act for Herbicides In a decisive move highlighting a shift towards strengthening domestic agricultural production, President Donald Trump signs…

    Cashu Finance·9 months ago

    U.S. DPA Boost for Glyphosate and Phosphorus Elevates U.S. Supply Stakes for Bayer AG

    U.S. DPA move on glyphosate and phosphorus places strategic spotlight on Bayer AG A presidential order invoking the Defense Production Act to boost domestic supplies of elemental phosphorus and glypho…

    Cashu Finance·9 months ago

    Bayer AG presses $10.5 billion plan to resolve Roundup cancer litigation

    Bayer presses $10.5 billion plan to resolve Roundup cancer litigation Bayer AG is pushing a $10.5 billion settlement package to resolve current and future U.S. lawsuits alleging its Roundup weedkiller…

    Cashu Finance·9 months ago

    Bayer AG proposes $10.5B settlement package to resolve Roundup U.S. cancer lawsuits

    Bayer moves to cap Roundup litigation with $10.5 billion settlement package Bayer AG announces a proposed $10.5 billion package to resolve current and future U.S. lawsuits that allege its Roundup weed…

    Cashu Finance·9 months ago
    49 214 30 1
    Websitehttps://www.bayer.com